DAY ONEWednesday, 14 November, 2018
8:00
Conference Registration and Welcome Refreshments
8:30
Chairperson’s Welcome and Opening Remarks
Nicola Galtieri
Head of Compliance
Boehringer Ingelheim (Italy)
Walking the Fine Line of Partnering with Patients
8:35
Compliance Aspects of Industry-Patient Interactions
Ursula Hohlneicher
Senior Compliance Director
AstraZeneca (Sweden)
9:20
Key Considerations for Building Successful Patient Advisory Boards
Peter Rupprecht
Head of Compliance Global Healthcare Functions, Group Legal & Compliance
Merck KGaA (Germany)
9:50
SANOFI CASE STUDY An End-to-End Analysis of Fair Market Value from Contracting to Disclosure
Nicholas Pimlett
VP, Global head of Healthcare Transparency
Sanofi (USA)
10:20
Ask the Experts Q&A
Peter Rupprecht
Head of Compliance Global Healthcare Functions, Group Legal & Compliance
Merck KGaA (Germany)
Nicholas Pimlett
VP, Global head of Healthcare Transparency
Sanofi (USA)
10:30
Networking and Refreshment Break
Explore the New Frontier in Competition Law and Whistleblower Protection
11:00
An Overview of Competition Law
Mukundan Bharathan
Regional General Counsel — Europe
Dr. Reddy’s Laboratories SA (Switzerland)
11:45
Examine Whistleblower Protection in the EU
Ulf Grundmann
Partner
King & Spalding (Germany)
12:30
Networking Luncheon
13:30
INVITATION-ONLY
Chief Compliance Officer Summit
2018 Theme: Compliance as a Contributive Force This summit is designed to encourage an open exchange of ideas and strategies surrounding some of the most critical issues facing heads of compliance across the life sciences industry. The host facilitates discussions surrounding key questions, challenges and issues. Participants benefit from exclusive networking with peers, sharing concerns and acquiring additional best practices for enriching their compliance programmes.
DIALOGUE STARTERS:
I.Global data privacy and data management
II.Transparency’s role in changing the competitive intelligence landscape
III.Quality measures — Are our KPIs powerful enough?
IV.Emerging technologies and trends
V.Building public trust and confidence
*Invited participants hold the title of Chief Compliance Officer, Vice President of Compliance, General Counsel or an equivalent compliance leadership position at a life sciences company (at the time of the conference). Final eligibility approval is at the discretion of CBI.
FACILITATOR:
David Eves
Head of Compliance
Chugai Pharma Europe Ltd (UK)
15:00
Close of CCO Summit
13:30
Six Months into GDPR — Now What Do We Do?
Munish Duvedi
Business Consultant
GCO Consultancy (Netherlands)
14:15
“It’s Just Good Business” — How Transparency Can Bolster Business Strategy
Diva Duong
Global Compliance Solutions Partner
IQVIA (France)
15:00
Networking and Refreshment Break
15:30
The Global Transparency Arena: Activities, Insights and Challenges
Rachel Cooper
Director, Pharmaceuticals and Healthcare Programme
Transparency International (UK)
Reinforce and Streamline Global HCP/HCO Interactions
16:15
ABPI & ABHI SPOTLIGHTAn Update on Current MedTech and Pharmaceutical Guidelines for HCP Engagement
Karen Borrer
Head of Corporate Communication
The Association of the British Pharmaceutical Industry (ABPI) (UK)
Andrew Davies
Director, Market Access
The Association of the British Pharmaceutical Industry (ABPI) (UK)
17:00
Establish a Comprehensive Framework for HCP Risk Management
Brian Sharkey
Vice President and Privacy Officer
Porzio Life Sciences, LLC (USA)
Michael O’Connor
Vice President, Compliance Technology
Porzio Life Sciences, LLC (USA)
17:45
Close of Day One
Networking, Wine and Cheese Reception immediately following the final session on day one. Sponsored by: 
DAY TWOThursday, 15 November, 2018
8:00
Morning Refreshments
8:30
Chairperson’s Review of Day One
Nicola Galtieri
Head of Compliance
Boehringer Ingelheim (Italy)
8:40
IFPMA SPOTLIGHTDeep Dive into Evolving International Best Practices
Sofie Melis
Senior Manager, Ethics & Compliance
International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) (Switzerland)
9:20
Economic Sanctions Training for Life Sciences
Ramsey Jurdi
Partner
DLA Piper (Dubai)
10:00
EMERGING MARKETS EXCHANGEAnti-Bribery and Anti-Corruption Risk Hot Spots
For global life sciences companies, it is critical to consistently explore and expand into new markets from both a business- and risk-based profile. Gain a quick update on ABAC risks in a number of areas, including BRIC (Brazil, Russia, India and China), Eastern Europe, the Middle East and Africa.
Mirjam Weisse
Senior Director, Head of Compliance EMEA
Merz Pharma GmBH & Co. (Germany)
Karolina Czernicka-Kuhl
Director, Legal & Compliance DACH, Eastern Europe, Middle East
Vertex Pharmaceuticals (Germany)
10:45
Networking and Refreshment Break
Promoting Ethical Behaviors Internally and with Partners
11:15
FIRESIDE CHAT Strengthen Third-Party Compliance from Vetting to Monitoring
MODERATOR:
Mario Prohasky
Principal, EMEA Compliance Consulting Practice Leader
IQVIA (USA)
Q&A WITH:
Mirjam Weisse
Senior Director, Head of Compliance EMEA
Merz Pharma GmBH & Co. (Germany)
Pia Vining
Senior Director, Due Diligence
TRACE International (USA)
Evgeny Tilezhinsky
Law and Compliance Lead for the Central and Eastern Europe
Bristol-Myers Squibb
12:00
New Approaches to Compliance Assurance
Detlef Geiges
Senior Director Assurance, Global Methodology & Europe & Russia, Eurasia Lead, AstraZeneca Global Sustainability/Compliance
AstraZeneca (Germany)
12:45
Networking Luncheon
13:45
Collaborative PresentationEmbedding Compliance into the Business’s DNA at the Local and Global Levels
Maike Bermueller
Senior Legal Counsel, Global Healthcare Compliance Officer
Boehringer Ingelheim (Germany)
Kyriaki Merakli
Group Compliance Officer
Helsinn Group (Switzerland)
14:30
Twitter, Facebook and Everything In-Between —
Structuring Communications in a Risky Environment
Malene Hammerich Abildstrom
Ethics & Compliance Director
Astellas Pharma (Denmark)
15:15
Close of Conference
DAY ONEWednesday, 14 November, 2018
8:00
Conference Registration and Welcome Refreshments
8:30
Chairperson’s Welcome and Opening Remarks
Nicola Galtieri
Head of Compliance
Boehringer Ingelheim (Italy)
Walking the Fine Line of Partnering with Patients
8:35
Compliance Aspects of Industry-Patient Interactions
Ursula Hohlneicher
Senior Compliance Director
AstraZeneca (Sweden)
9:20
Key Considerations for Building Successful Patient Advisory Boards
Peter Rupprecht
Head of Compliance Global Healthcare Functions, Group Legal & Compliance
Merck KGaA (Germany)
9:50
SANOFI CASE STUDY An End-to-End Analysis of Fair Market Value from Contracting to Disclosure
Nicholas Pimlett
VP, Global head of Healthcare Transparency
Sanofi (USA)
10:20
Ask the Experts Q&A
Peter Rupprecht
Head of Compliance Global Healthcare Functions, Group Legal & Compliance
Merck KGaA (Germany)
Nicholas Pimlett
VP, Global head of Healthcare Transparency
Sanofi (USA)
10:30
Networking and Refreshment Break
Explore the New Frontier in Competition Law and Whistleblower Protection
11:00
An Overview of Competition Law
Mukundan Bharathan
Regional General Counsel — Europe
Dr. Reddy’s Laboratories SA (Switzerland)
11:45
Examine Whistleblower Protection in the EU
Ulf Grundmann
Partner
King & Spalding (Germany)
12:30
Networking Luncheon
13:30
INVITATION-ONLY
Chief Compliance Officer Summit
2018 Theme: Compliance as a Contributive Force This summit is designed to encourage an open exchange of ideas and strategies surrounding some of the most critical issues facing heads of compliance across the life sciences industry. The host facilitates discussions surrounding key questions, challenges and issues. Participants benefit from exclusive networking with peers, sharing concerns and acquiring additional best practices for enriching their compliance programmes.
DIALOGUE STARTERS:
I.Global data privacy and data management
II.Transparency’s role in changing the competitive intelligence landscape
III.Quality measures — Are our KPIs powerful enough?
IV.Emerging technologies and trends
V.Building public trust and confidence
*Invited participants hold the title of Chief Compliance Officer, Vice President of Compliance, General Counsel or an equivalent compliance leadership position at a life sciences company (at the time of the conference). Final eligibility approval is at the discretion of CBI.
FACILITATOR:
David Eves
Head of Compliance
Chugai Pharma Europe Ltd (UK)
15:00
Close of CCO Summit
13:30
Six Months into GDPR — Now What Do We Do?
Munish Duvedi
Business Consultant
GCO Consultancy (Netherlands)
14:15
“It’s Just Good Business” — How Transparency Can Bolster Business Strategy
Diva Duong
Global Compliance Solutions Partner
IQVIA (France)
15:00
Networking and Refreshment Break
15:30
The Global Transparency Arena: Activities, Insights and Challenges
Rachel Cooper
Director, Pharmaceuticals and Healthcare Programme
Transparency International (UK)
Reinforce and Streamline Global HCP/HCO Interactions
16:15
ABPI & ABHI SPOTLIGHTAn Update on Current MedTech and Pharmaceutical Guidelines for HCP Engagement
Karen Borrer
Head of Corporate Communication
The Association of the British Pharmaceutical Industry (ABPI) (UK)
Andrew Davies
Director, Market Access
The Association of the British Pharmaceutical Industry (ABPI) (UK)
17:00
Establish a Comprehensive Framework for HCP Risk Management
Brian Sharkey
Vice President and Privacy Officer
Porzio Life Sciences, LLC (USA)
Michael O’Connor
Vice President, Compliance Technology
Porzio Life Sciences, LLC (USA)
17:45
Close of Day One
Networking, Wine and Cheese Reception immediately following the final session on day one. Sponsored by:
DAY TWOThursday, 15 November, 2018
8:00
Morning Refreshments
8:30
Chairperson’s Review of Day One
Nicola Galtieri
Head of Compliance
Boehringer Ingelheim (Italy)
8:40
IFPMA SPOTLIGHTDeep Dive into Evolving International Best Practices
Sofie Melis
Senior Manager, Ethics & Compliance
International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) (Switzerland)
9:20
Economic Sanctions Training for Life Sciences
Ramsey Jurdi
Partner
DLA Piper (Dubai)
10:00
EMERGING MARKETS EXCHANGEAnti-Bribery and Anti-Corruption Risk Hot Spots
For global life sciences companies, it is critical to consistently explore and expand into new markets from both a business- and risk-based profile. Gain a quick update on ABAC risks in a number of areas, including BRIC (Brazil, Russia, India and China), Eastern Europe, the Middle East and Africa.
Mirjam Weisse
Senior Director, Head of Compliance EMEA
Merz Pharma GmBH & Co. (Germany)
Karolina Czernicka-Kuhl
Director, Legal & Compliance DACH, Eastern Europe, Middle East
Vertex Pharmaceuticals (Germany)
10:45
Networking and Refreshment Break
Promoting Ethical Behaviors Internally and with Partners
11:15
FIRESIDE CHAT Strengthen Third-Party Compliance from Vetting to Monitoring
MODERATOR:
Mario Prohasky
Principal, EMEA Compliance Consulting Practice Leader
IQVIA (USA)
Q&A WITH:
Mirjam Weisse
Senior Director, Head of Compliance EMEA
Merz Pharma GmBH & Co. (Germany)
Pia Vining
Senior Director, Due Diligence
TRACE International (USA)
Evgeny Tilezhinsky
Law and Compliance Lead for the Central and Eastern Europe
Bristol-Myers Squibb
12:00
New Approaches to Compliance Assurance
Detlef Geiges
Senior Director Assurance, Global Methodology & Europe & Russia, Eurasia Lead, AstraZeneca Global Sustainability/Compliance
AstraZeneca (Germany)
12:45
Networking Luncheon
13:45
Collaborative PresentationEmbedding Compliance into the Business’s DNA at the Local and Global Levels
Maike Bermueller
Senior Legal Counsel, Global Healthcare Compliance Officer
Boehringer Ingelheim (Germany)
Kyriaki Merakli
Group Compliance Officer
Helsinn Group (Switzerland)
14:30
Twitter, Facebook and Everything In-Between —
Structuring Communications in a Risky Environment
Malene Hammerich Abildstrom
Ethics & Compliance Director
Astellas Pharma (Denmark)
15:15
Close of Conference
